PATENT COOPERATION TREATY

		The state of the s		. ~,_
REC'D	24	MAY	2005	İ
WIPO			.5 .*	~· [{]

From the	•
INTERNATIONAL	SEARCHING AUTHORITY

To:
Awapatent AB
Box 5117
200 71 Malmö

PCT

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

Sweden (PCT Rule 43bis.1) 17 -05- 2005 Date of mailing (day/month/year) FOR FURTHER ACTION Applicant's or agent's file reference See paragraph 2 below 21018060 Priority date (day/month/year) International filing date (day/month/year) International application No. 04.02.2004 19.01.2005 PCT/SE 2005/000054 International Patent Classification (IPC) or both national classification and IPC A61K 31/4025, 31/155, 31/195, C07D207/26,211/98,401/12,403/12, 215/00, A61P 19/00,37/00,21/00 **Applicant** Active Biotech AB et al

1.	I. This opinion contains indications relating to the following items:					
	\boxtimes	Box No. I	I Basis of the opinion II Priority			
		Box No. II				
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industri			d to novelty, inventive step and industrial applicability			
		Box No. IV	Lack of unity of invention			
	$\overline{\boxtimes}$	Box No. V	No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
		Box No. VI	Certain documents cited			
	Ħ		Certain defects in the international appli			
		Box No. VIII	Certain observations on the international	application		
 FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses Authority other than this one to be IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1b written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further opinions, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. 				has notified the International Bureau under Rule 66.1 bis(b) that I not be so considered. In opinion of the IPEA, the applicant is invited to submit to the Iments before the expiration of 3 months from the date of mailing		
1	Vame 8	nd mailing add	ress of the ISA/SE	Authorized officer		
Patent- och registreringsverket Box 5055		•	Fernando Farieta/ELY			
- 1		42 STOCKHO	3 667 72 88 ·	Telephone No. +46 8 782 25 00		

Form PCT/ISA/237 (cover sheet) (January 2004)

International application No.

PCT/SE 2005/000054

Box	No. 1	Basis of this opinion
1.	which it	gard to the language, this opinion has been established on the basis of the international application in the language in was filed, unless otherwise indicated under this item. This opinion has been established on the basis of a translation from the original language into the following language, , which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
	claimed	gard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the invention, this opinion has been established on the basis of: of material a sequence listing table(s) related to the sequence listing
	b. forma	t of material in written format in computer readable form
	c. time	of filing/furnishing contained in the international application as filed. filed together with the international application in computer readable form. furnished subsequently to this Authority for the purposes of search.
3.		In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Addition	nal comments:
	•	

International application No.

PCT/SE 2005/00054

Box No. II Priority				
1. The following document has not yet been furnished:				
copy of the earlier application whose priority has been claimed (Rules 43bis.1 and 66.7(a))).			
translation of the earlier application whose priority has been claimed (Rules 43bis.1 and 66				
Consequently it has not been possible to consider the validity of the priority claim. This opinion has established on the assumption that the relevant date is the claimed priority date.	s nevertheless been			
This opinion has been established as if no priority had been claimed due to the fact that the priority found invalid (Rules 43bis.1 and 64.1). Thus for the purposes of this opinion, the international filing above is considered to be the relevant date.	claim has been g date indicated			
3. Additional observations, if necessary:				
The priority is considered valid.				
÷				
	- 20			
<u>-</u>				

Form PCT/ISA/237 (Box No. II) (January 2004)

International application No.

PCT/SE 2005/000054

Box No. II	I Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
	on whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be applicable have not been examined in respect of:
	the entire international application
\boxtimes	claims Nos. 14-16
E	the said international application, or the said claims Nos. <u>14-16</u> relate to the following subject matter which does not require an international preliminary examination (specify):
	PCT Rule 67.1.(iv).: Methods for treatment of the human nimal body by surgery or therapy, as well as diagnostic ods.
٠	
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):
•	
—	The claims, or said claims Nos. are so inadequately supported
اــــا	by the description that no meaningful opinion could be formed.
	no international search report has been established for said claims Nos.
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:
	the written form has not been furnished
	does not comply with the standard the computer readable form has not been furnished does not comply with the standard
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in the Annex C-bis of the Administrative Instructions.
	See Supplemental Box for further details.

Form PCT/ISA/237 (Box No. III) (January 2004)

International application No.

PCT/SE 2005/00054

Box No. V	Reasoned statement u applicability; citation	nder Rule 4: s and explan	3bis.1(a)(i) with regard to novelty, inve- ations supporting such statement	ntive step or industrial
1. Statemer	nt			
Novel	lty (N)	Claims	1-13	YES
		Claims		NO
Inven	tive step (IS)	Claims	1-13	YES
		Claims		NO
Indus	trial applicability (IA)	Claims	1-13	YES
		Claims		NO NO
Indus	trial applicability (IA)	Claims	1-13	

2. Citations and explanations:

Documents cited in the International Search Report:

D1: WO 99/63929 A3

D2: WO 99/12912 A1

D3: WO 93/16992 A1

D4: EP 0325 397 A1

The cited documents represent the general state of the art. The invention defined in claims 1-13 is not disclosed by any of these documents.

The cited prior art does not give any indication that would lead a person skilled in the art to the claimed diureas. Therefore, the claimed invention is not obvious to a person skilled in the art.

Accordingly, the invention defined in claims 1-13 is novel and is considered to involve an inventive step. The invention is industrially applicable.